Hutch News

Hutch News

Stories tagged 'Matthias Stephan'

Improving cancer vaccines with T-cell programming nanoparticles

Dr. Matthias Stephan receives grant to develop cancer vaccine–optimizing, TCR-programming nanotechnology

July 31, 2018 | By Sabrina Richards / Fred Hutch News Service

Fred Hutch immunobioengineer Dr. Matthias Stephan has received an award to support the development of a combined T-cell programming, cancer-vaccine strategy to treat cancer.

View story >


Nanoparticles open doors to cancer-fighting CAR T cells

Tiny liposome-based drug carriers make tumors more vulnerable to targeted immunotherapy

July 2, 2018 | By Sabrina Richards / Fred Hutch News Service

Scientists at Fred Hutchinson Cancer Research Center have developed a cheap way to make cancers temporarily vulnerable to immune attack using liposome-based nanoparticles to carry immune-boosting drugs deep into tumors.

View story >


Nanoparticles take immunotherapy in new direction

Hutch scientist to use nanoparticles to reprogram macrophages to tackle brain tumors

May 30, 2018 | By Sabrina Richards / Fred Hutch News Service

Dr. Fan Zhang has received funding from the American Brain Tumor Association to develop nanoparticles that can tackle a type of brain cancer called glioblastoma.

View story >


10 highlights of Fred Hutch science in 2017

A look back at notable discoveries in cancer immunotherapy, HIV prevention and more

Dec. 28, 2017 | by Sabin Russell and Susan Keown / Fred Hutch News Service

It's been a year of breakthroughs at Fred Hutch. Here are 10 of our favorites.

View story >


New nanoparticles make targeted, temporary gene therapy possible

‘Hit-and-run’ technology could improve immunotherapy and HIV cure research

Aug. 30, 2017 | By Sabrina Richards / Fred Hutch News Service

'Hit-and-run' technology could improve immunotherapy and HIV cure research

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

May 25, 2017

A team of Fred Hutch researchers led by principal investigator Dr. Eric Holland has received $400,000 for a two-year pilot study to test several novel immunotherapy approaches for glioma, an aggressive brain cancer. The study was made possible by the generous support of the Bezos family, which since 2009 has donated and leveraged more than $40 million to Fred Hutch for immunotherapy research.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.